Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer.

Takeshi TerashimaChigusa MorizaneMineko UshiamaSatoshi ShibaHideaki TakahashiMasafumi IkedaNobumasa MizunoKunihiro TsujiKohichiroh YasuiNobuaki AzemotoHironaga SatakeShogo NomuraShinichi YachidaKokichi SuganoJunji Furuse

Published in: Japanese journal of clinical oncology (2022)

The prevalence of germline variants in PDAC patients was very low even among patients with a familial/personal history of pancreatic, breast, ovarian or prostate cancer. Patients with one or more germline variants in HRR-related genes classified as pathogenic or VUS may have the potential to obtain better response to GEMOX and have better outcomes.

Keyphrases

prostate cancer
papillary thyroid
copy number
dna repair
end stage renal disease
squamous cell
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
risk factors
gene expression
lymph node metastasis
adipose tissue
skeletal muscle
insulin resistance
weight loss
glycemic control
patient reported